JP7852200B2 - ウィルソン病を治療するためのビスコリンテトラチオモリブデート - Google Patents

ウィルソン病を治療するためのビスコリンテトラチオモリブデート

Info

Publication number
JP7852200B2
JP7852200B2 JP2020547315A JP2020547315A JP7852200B2 JP 7852200 B2 JP7852200 B2 JP 7852200B2 JP 2020547315 A JP2020547315 A JP 2020547315A JP 2020547315 A JP2020547315 A JP 2020547315A JP 7852200 B2 JP7852200 B2 JP 7852200B2
Authority
JP
Japan
Prior art keywords
biscolinetetrathiomolybdate
patient
disease
wilson
uwdrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020547315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505655A (ja
JP2021505655A5 (https=
Inventor
カール・ビャートマー
カール－ハインツ・ヴァイス
マイケル・シルスキー
フレドリック・アスカリ
アンナ・シャロンクォスカ
ペーター・フェレンチ
ペーター・ヘデラ
アフタブ・アラ
Original Assignee
アレクシオン・ファーマ・インターナショナル・オペレーションズ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン・ファーマ・インターナショナル・オペレーションズ・リミテッド filed Critical アレクシオン・ファーマ・インターナショナル・オペレーションズ・リミテッド
Publication of JP2021505655A publication Critical patent/JP2021505655A/ja
Publication of JP2021505655A5 publication Critical patent/JP2021505655A5/ja
Priority to JP2023038205A priority Critical patent/JP2023075247A/ja
Priority to JP2025010250A priority patent/JP2025066802A/ja
Application granted granted Critical
Publication of JP7852200B2 publication Critical patent/JP7852200B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020547315A 2017-12-04 2018-12-04 ウィルソン病を治療するためのビスコリンテトラチオモリブデート Active JP7852200B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023038205A JP2023075247A (ja) 2017-12-04 2023-03-13 ウィルソン病を治療するためのビスコリンテトラチオモリブデート
JP2025010250A JP2025066802A (ja) 2017-12-04 2025-01-24 ウィルソン病を治療するためのビスコリンテトラチオモリブデート

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201762594184P 2017-12-04 2017-12-04
US62/594,184 2017-12-04
US201862646553P 2018-03-22 2018-03-22
US62/646,553 2018-03-22
US201862655568P 2018-04-10 2018-04-10
US62/655,568 2018-04-10
US201862669095P 2018-05-09 2018-05-09
US62/669,095 2018-05-09
US201862741313P 2018-10-04 2018-10-04
US62/741,313 2018-10-04
US201862750595P 2018-10-25 2018-10-25
US62/750,595 2018-10-25
PCT/EP2018/083551 WO2019110619A1 (en) 2017-12-04 2018-12-04 Bis-choline tetrathiomolybdate for treating wilson disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023038205A Division JP2023075247A (ja) 2017-12-04 2023-03-13 ウィルソン病を治療するためのビスコリンテトラチオモリブデート

Publications (3)

Publication Number Publication Date
JP2021505655A JP2021505655A (ja) 2021-02-18
JP2021505655A5 JP2021505655A5 (https=) 2022-01-11
JP7852200B2 true JP7852200B2 (ja) 2026-04-28

Family

ID=64661349

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020547315A Active JP7852200B2 (ja) 2017-12-04 2018-12-04 ウィルソン病を治療するためのビスコリンテトラチオモリブデート
JP2023038205A Pending JP2023075247A (ja) 2017-12-04 2023-03-13 ウィルソン病を治療するためのビスコリンテトラチオモリブデート
JP2025010250A Pending JP2025066802A (ja) 2017-12-04 2025-01-24 ウィルソン病を治療するためのビスコリンテトラチオモリブデート

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023038205A Pending JP2023075247A (ja) 2017-12-04 2023-03-13 ウィルソン病を治療するためのビスコリンテトラチオモリブデート
JP2025010250A Pending JP2025066802A (ja) 2017-12-04 2025-01-24 ウィルソン病を治療するためのビスコリンテトラチオモリブデート

Country Status (16)

Country Link
US (3) US11510944B2 (https=)
EP (3) EP4523745A3 (https=)
JP (3) JP7852200B2 (https=)
KR (1) KR102803161B1 (https=)
AU (1) AU2018379255B2 (https=)
BR (1) BR112020011055A2 (https=)
DK (2) DK4029498T3 (https=)
ES (2) ES3026756T3 (https=)
FI (1) FI4029498T3 (https=)
HU (2) HUE071155T2 (https=)
IL (1) IL275115B2 (https=)
MX (1) MX2020006284A (https=)
PL (2) PL4029498T3 (https=)
PT (2) PT4029498T (https=)
SI (2) SI4029498T1 (https=)
WO (1) WO2019110619A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
MX2020006284A (es) * 2017-12-04 2021-04-12 Alexion Pharma Int Operations Unlimited Company Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
WO2019154876A1 (en) 2018-02-06 2019-08-15 Wilson Therapeutics Ab Crystalline particles of bis-choline tetrathiomolybdate
US20220387370A1 (en) 2019-11-21 2022-12-08 Alexion Pharmaceuticals, Inc. Methods of reducing neurological damage in wilson disease patients
CN116601173A (zh) * 2020-09-11 2023-08-15 阿雷克森制药公司 抗铜蓝蛋白抗体及其用途
EP4243806A1 (en) * 2020-11-13 2023-09-20 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders
JP2024505229A (ja) * 2021-01-31 2024-02-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 銅代謝関連疾患又は障害を治療するための新規製剤
WO2023023199A1 (en) 2021-08-17 2023-02-23 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders
WO2024162974A1 (en) 2023-01-30 2024-08-08 Alexion Pharmaceuticals, Inc. Tetrathiomolybdic acid for use in treating copper metabolism-associated diseases or disorders (wilson disease)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538093A (ja) 2002-07-23 2005-12-15 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 抗血管形成療法のための、テトラポリアンモニウムテトラチオモリブデートおよび関連化合物
JP2006506466A (ja) 2002-07-23 2006-02-23 アテニュオン，リミティド ライアビリティー カンパニー チオモリブデン酸類似物及びそれらの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2675230A1 (en) 2006-01-10 2008-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
MX2020006284A (es) 2017-12-04 2021-04-12 Alexion Pharma Int Operations Unlimited Company Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
WO2019154876A1 (en) 2018-02-06 2019-08-15 Wilson Therapeutics Ab Crystalline particles of bis-choline tetrathiomolybdate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538093A (ja) 2002-07-23 2005-12-15 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 抗血管形成療法のための、テトラポリアンモニウムテトラチオモリブデートおよび関連化合物
JP2006506466A (ja) 2002-07-23 2006-02-23 アテニュオン，リミティド ライアビリティー カンパニー チオモリブデン酸類似物及びそれらの使用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Hepatology, 2017年10月, 発行日, Vol.66, No.1(Suppl), p.429A, Abstract 802
Journal of Hepatology, 2017年04月, 発行日, Vol.66, p.S88, Abstract GS-016
Lancet Gastroenterol Hepatol, 2017年10月05日, 発行日, Vol.2, pp.869-876
Movement Disorders, 2017年06月, 発行日, Vol.32, Suppl.2, p.S455, Abstract 1184
岡山医学会雑誌, 2015年, 発行日, Vol.127, pp.245-249

Also Published As

Publication number Publication date
EP4029498B1 (en) 2025-02-05
ES2912306T3 (es) 2022-05-25
EP3720433A1 (en) 2020-10-14
IL275115B1 (en) 2025-06-01
EP4523745A3 (en) 2025-05-14
DK3720433T3 (da) 2022-05-02
HUE058921T2 (hu) 2022-09-28
JP2021505655A (ja) 2021-02-18
IL275115A (en) 2020-07-30
PT4029498T (pt) 2025-05-06
RU2020122023A (ru) 2022-01-10
AU2018379255B2 (en) 2024-10-17
HUE071155T2 (hu) 2025-08-28
PT3720433T (pt) 2022-05-03
US20210137972A1 (en) 2021-05-13
KR102803161B1 (ko) 2025-05-07
MX2020006284A (es) 2021-04-12
US20230070534A1 (en) 2023-03-09
DK4029498T3 (da) 2025-04-28
EP4523745A2 (en) 2025-03-19
FI4029498T3 (fi) 2025-04-29
US20210177894A1 (en) 2021-06-17
PL3720433T3 (pl) 2022-07-18
WO2019110619A1 (en) 2019-06-13
KR20200096798A (ko) 2020-08-13
AU2018379255A1 (en) 2020-06-25
BR112020011055A2 (pt) 2020-11-17
ES3026756T3 (en) 2025-06-12
JP2025066802A (ja) 2025-04-23
EP4029498A1 (en) 2022-07-20
IL275115B2 (en) 2025-10-01
SI3720433T1 (sl) 2022-09-30
US11510944B2 (en) 2022-11-29
EP3720433B1 (en) 2022-02-02
US12233088B2 (en) 2025-02-25
CA3084100A1 (en) 2019-06-13
SI4029498T1 (sl) 2025-07-31
PL4029498T3 (pl) 2025-06-02
JP2023075247A (ja) 2023-05-30

Similar Documents

Publication Publication Date Title
JP7852200B2 (ja) ウィルソン病を治療するためのビスコリンテトラチオモリブデート
JP2024180450A (ja) ５－ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法
US20220152055A1 (en) Methods and compositions for treating various disorders
CN103974619B (zh) 治疗法布里病的给药方案
US11419832B2 (en) Bis-choline tetrathiomolybdate for treating Wilson Disease
TWI879741B (zh) 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
JP2008513491A (ja) 自閉症、強迫神経症、および衝動性の治療のためのメマンチン（ナメンダ）の使用
US20180311217A1 (en) Methods of treatment and compositions with xanthine oxidase inhibitors
CA3084100C (en) Bis-choline tetrathiomolybdate for treating wilson disease
EP3381455A1 (en) Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
JP2021530569A (ja) 自閉症を処置するための組成物および方法
RU2787632C2 (ru) Бис-холина тетратиомолибдат для лечения болезни вильсона
CA3230084A1 (en) Methods of treating copper metabolism-associated diseases or disorders
US20250375417A1 (en) Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1)
CN121358471A (zh) 用于治疗铜代谢相关疾病或病症(威尔逊病)的四硫代钼酸
HK40081935A (en) Treatment of amyotrophic lateral sclerosis
EA051453B1 (ru) Способы лечения и профилактики рассеянного склероза с применением соединений замещенного аминопиримидина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231013

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231127

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260326